MDP-based postbiotics via NOD2 act as insulin sensitizers, as indicated by reduced adipose tissue inflammation and reduced glucose intolerance in mice with obesity without the alteration of gut microbiota and weight loss [111]. Here, NOD2 is linked to obesity due to melanocortin 4 receptor deficiency.